PALVELLA THERAPEUTICS, INC.PVLAEarnings & Financial Report
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for rare, debilitating genetic diseases with high unmet medical needs. Its lead product candidates address congenital disorders, serving global patient populations that lack effective existing treatment options.
Revenue
$690.0K
Gross Profit
N/A
Operating Profit
$-9.3M
Net Profit
$-9.5M
Gross Margin
N/A
Operating Margin
-1340.6%
Net Margin
-1372.6%
YoY Growth
N/A
EPS
$-0.86
PALVELLA THERAPEUTICS, INC. Q2 FY2025 Financial Summary
PALVELLA THERAPEUTICS, INC. reported revenue of $690.0K for Q2 FY2025, with a net profit of $-9.5M (down 127.0% YoY) (-1372.6% margin).
Key Financial Metrics
| Total Revenue | $690.0K |
|---|---|
| Net Profit | $-9.5M |
| Gross Margin | N/A |
| Operating Margin | -1340.6% |
| Report Period | Q2 FY2025 |
PALVELLA THERAPEUTICS, INC. Annual Revenue by Year
PALVELLA THERAPEUTICS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $2.6M).
| Year | Annual Revenue |
|---|---|
| 2025 | $2.6M |
| 2023 | $42.8M |
| 2022 | $25.9M |
PALVELLA THERAPEUTICS, INC. Quarterly Revenue & Net Profit History
PALVELLA THERAPEUTICS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $520.0K | +14.3% | N/A | N/A |
| Q3 FY2025 | $628.0K | — | $-11.3M | -1806.5% |
| Q2 FY2025 | $690.0K | — | $-9.5M | -1372.6% |
| Q1 FY2025 | $752.0K | +1318.9% | $-8.2M | -1088.4% |
| Q3 FY2024 | $0 | — | $-6.8M | N/A |
| Q2 FY2024 | $0 | — | $-4.2M | N/A |
| Q1 FY2024 | $53.0K | -97.3% | $-2.5M | -4784.9% |
| Q4 FY2023 | $1.3M | -77.8% | N/A | N/A |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $53000 | $0 | $0 | $752000 | $690000 | $628000 | $520000 |
| YoY Growth | -77.8% | -97.3% | N/A | N/A | 1318.9% | N/A | N/A | 14.3% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $7.5M | $29.5M | $25.1M | $20.5M | $79.4M | $73.7M | $66.9M | $59.6M |
| Liabilities | $11.4M | $106.4M | $105.9M | $107.9M | $23.9M | $26.0M | $28.3M | $31.6M |
| Equity | $-74.5M | $-76.9M | $-80.8M | $-87.4M | $55.6M | $47.8M | $38.7M | $28.0M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-13.7M | $-1.1M | $-1.6M | $-2.7M | $-6.8M | $-5.4M | $-7.9M | $-25.0M |